|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: LIN37 |
Gene summary for LIN37 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | LIN37 | Gene ID | 55957 |
| Gene name | lin-37 DREAM MuvB core complex component | |
| Gene Alias | F25965 | |
| Cytomap | 19q13.12 | |
| Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | Q96GY3 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 55957 | LIN37 | LZE4T | Human | Esophagus | ESCC | 1.70e-03 | 1.29e-01 | 0.0811 |
| 55957 | LIN37 | LZE20T | Human | Esophagus | ESCC | 1.26e-02 | 1.17e-01 | 0.0662 |
| 55957 | LIN37 | LZE24T | Human | Esophagus | ESCC | 6.88e-12 | 2.63e-01 | 0.0596 |
| 55957 | LIN37 | LZE21T | Human | Esophagus | ESCC | 6.52e-03 | 2.04e-01 | 0.0655 |
| 55957 | LIN37 | P1T-E | Human | Esophagus | ESCC | 5.20e-08 | 2.75e-01 | 0.0875 |
| 55957 | LIN37 | P2T-E | Human | Esophagus | ESCC | 3.07e-06 | 1.76e-01 | 0.1177 |
| 55957 | LIN37 | P4T-E | Human | Esophagus | ESCC | 2.81e-07 | 1.81e-01 | 0.1323 |
| 55957 | LIN37 | P5T-E | Human | Esophagus | ESCC | 1.50e-14 | 2.44e-01 | 0.1327 |
| 55957 | LIN37 | P8T-E | Human | Esophagus | ESCC | 1.22e-26 | 4.41e-01 | 0.0889 |
| 55957 | LIN37 | P9T-E | Human | Esophagus | ESCC | 1.23e-14 | 3.18e-01 | 0.1131 |
| 55957 | LIN37 | P10T-E | Human | Esophagus | ESCC | 3.39e-31 | 4.89e-01 | 0.116 |
| 55957 | LIN37 | P11T-E | Human | Esophagus | ESCC | 3.75e-08 | 2.64e-01 | 0.1426 |
| 55957 | LIN37 | P12T-E | Human | Esophagus | ESCC | 6.60e-11 | 2.04e-01 | 0.1122 |
| 55957 | LIN37 | P15T-E | Human | Esophagus | ESCC | 5.37e-05 | 1.26e-01 | 0.1149 |
| 55957 | LIN37 | P16T-E | Human | Esophagus | ESCC | 1.02e-08 | 1.77e-01 | 0.1153 |
| 55957 | LIN37 | P17T-E | Human | Esophagus | ESCC | 1.49e-05 | 2.36e-01 | 0.1278 |
| 55957 | LIN37 | P20T-E | Human | Esophagus | ESCC | 1.73e-12 | 2.60e-01 | 0.1124 |
| 55957 | LIN37 | P21T-E | Human | Esophagus | ESCC | 2.66e-06 | 1.31e-01 | 0.1617 |
| 55957 | LIN37 | P22T-E | Human | Esophagus | ESCC | 5.47e-10 | 2.31e-01 | 0.1236 |
| 55957 | LIN37 | P23T-E | Human | Esophagus | ESCC | 9.64e-32 | 5.46e-01 | 0.108 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0421829 | Esophagus | ESCC | Cellular senescence | 119/4205 | 156/8465 | 5.89e-12 | 9.40e-11 | 4.81e-11 | 119 |
| hsa0421838 | Esophagus | ESCC | Cellular senescence | 119/4205 | 156/8465 | 5.89e-12 | 9.40e-11 | 4.81e-11 | 119 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| LIN37 | SNV | Missense_Mutation | rs368622689 | c.371G>A | p.Arg124His | p.R124H | Q96GY3 | protein_coding | tolerated(0.18) | probably_damaging(0.922) | TCGA-B6-A409-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | PD |
| LIN37 | SNV | Missense_Mutation | novel | c.561G>C | p.Glu187Asp | p.E187D | Q96GY3 | protein_coding | tolerated(0.38) | benign(0.351) | TCGA-OL-A5RZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR |
| LIN37 | SNV | Missense_Mutation | novel | c.415C>T | p.Pro139Ser | p.P139S | Q96GY3 | protein_coding | deleterious(0.02) | benign(0.165) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| LIN37 | SNV | Missense_Mutation | novel | c.637N>T | p.Arg213Cys | p.R213C | Q96GY3 | protein_coding | deleterious(0) | benign(0.198) | TCGA-MA-AA42-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
| LIN37 | SNV | Missense_Mutation | c.225N>C | p.Lys75Asn | p.K75N | Q96GY3 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-MY-A5BE-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| LIN37 | SNV | Missense_Mutation | novel | c.564N>A | p.Met188Ile | p.M188I | Q96GY3 | protein_coding | tolerated(0.2) | benign(0) | TCGA-VS-A9UJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
| LIN37 | SNV | Missense_Mutation | novel | c.734G>A | p.Arg245Gln | p.R245Q | Q96GY3 | protein_coding | deleterious(0.01) | benign(0.099) | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| LIN37 | SNV | Missense_Mutation | rs556772764 | c.691C>T | p.Arg231Cys | p.R231C | Q96GY3 | protein_coding | deleterious(0) | probably_damaging(0.981) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| LIN37 | SNV | Missense_Mutation | rs199515554 | c.626G>A | p.Arg209His | p.R209H | Q96GY3 | protein_coding | tolerated(0.12) | benign(0.202) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| LIN37 | SNV | Missense_Mutation | novel | c.121G>A | p.Asp41Asn | p.D41N | Q96GY3 | protein_coding | tolerated(0.29) | benign(0.038) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |